Skip to main content

Table 3 Acute adverse events (AEs) during neoadjuvant therapy in Group C and Group D

From: Current status of neoadjuvant therapy for locally advanced rectal cancer in Wuhan Union Hospital Cancer Center

 

Group C (n = 170)

Group D (n = 98)

Grade 1–2 (%)

Grade 3–4 (%)

Grade 1–2 (%)

Grade 3–4 (%)

Leukopenia

107 (62.9)

16 (9.4)

57 (58.2)

8 (8.2)

Neutropenia

76 (44.7)

19 (11.2)

42 (42.9)

13 (13.3)

Anemia

63 (37.1)

6 (3.5)

34 (34.7)

5 (5.1)

Thrombocytopenia

31 (18.2)

2 (1.2)

22 (22.4)

0 (0.0)

Radiation proctitis

96 (56.5)

0 (0.0)

36 (36.7)

0 (0.0)